Latest Breaking News On - Patrick burnett - Page 1 : vimarsana.com

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Call Transcript

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

Roflumilast improves atopic dermatitis symptoms in children aged 2 to 5 years

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.72 EPS, expectations were $-0.65. Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript February 27, 2024 Arcutis Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.72 EPS, expectations were $-0.65. Arcutis Biotherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day […]

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% ...

Novel steroid-free topical foam effectively controls seborrheic dermatitisOnce-daily ZORYVE® (roflumilast) topical foam, 0.3%, is approved to treat seborrheic dermatitis in individuals 9 years of age and older

Journal Of The American Academy Of Dermatology Publishes ZORYVE (Roflumilast) Foam, 0.3% Results For Seborrheic Dermatitis From Pivotal Phase 3 Trial

Vast Majority of Atopic Dermatitis Patients Show EASI Improvement with 4 Weeks of Roflumilast Cream

These data, presented at the Winter Clinical conference, showed that roflumilast cream 0.15% led to positive results for patients with eczema.

Roflumilast Foam Effective for Seborrheic Dermatitis Patients Inadequately Responding to Steroids

In this subgroup analysis data shown at Winter Clinical, findings indicated IGA success with topical roflumilast foam among seborrheic dermatitis patients.